Market Research Logo

BioSeeker Group AB

BioSeeker Group is a business and competitive intelligence company for investment, venture and R&D management of biotechnology and pharmaceutical companies. It serves the needs of individuals, companies, and institutional clients with a diverse range of information and analysis services.

BioSeeker Group has a strong client focus providing decision-makers, investors, and management people with candid, credible research coverage on biotechnology and pharmaceutical companies. The firm is committed to creating value for clients by providing wisdom and high quality services that meet clients' needs. BioSeeker's clients and projects are kept confidential.

...Show More ...Show Less

222 Reports from BioSeeker Group AB

   
  • Proteins in Oncology Drug Pipeline Update

    ... developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 207 drugs. Proteins In Oncology Drug Pipeline Update lists all ... Read More

  • IL-7 Signaling Pathway in Oncology Drug Pipeline Update

    ... in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 36 drugs. Il-7 Signaling Pathway In Oncology Drug Pipeline Update lists all ... Read More

  • IL-9 Signaling Pathway in Oncology Drug Pipeline Update

    ... projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 35 drugs. Il-9 Signaling Pathway In Oncology Drug Pipeline Update lists ... Read More

  • Leptin Signaling Pathway in Oncology Drug Pipeline Update

    ... developing 537 Leptin pathway targeting drugs in 1840 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 229 drugs. ... Read More

  • Gastrointestinal Cancer Drug Pipeline Update

    ... of ceased drugs over the last years amount to another 80 drugs. Gastrointestinal Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked ... Read More

  • Epigenetic Therapy in Oncology Drug Pipeline Update

    ... to date there are several approved epigenetic drugs in oncology (eg, Azacitidine, Decitabine, Vorinostat, Romidepsin, Ruxolitinib). Today a majority of drugs targets histone methylation and acetylation, also frequently dysregulated in cancer cells, in the form ... Read More

  • Adherens Junction Targeting in Oncology Drug Pipeline Update

    ... There are today 277 companies plus partners developing 357 targeting adherens junctions drugs in 1199 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the ... Read More

  • Targeting Immune Checkpoints in Cancer Immunotherapy Drug Pipeline Update

    ... get on this hot and fast moving area in cancer immunology. There are two sides of immune checkpoint control; those which activate and those which inhibit T-cell activation. BioSeeker’s Targeting Immune Checkpoints in Cancer Immunotherapy: ... Read More

  • Biosimilars in Oncology Drug Pipeline Update

    ... As patent protection for some of the most widely used biologics in cancer begins to expire, the competition will make a hot entry with biosimilars which will have the potential to increase access and provide ... Read More

  • Cancer Drugs in the FDA Fast Lane Drug Pipeline Update

    ... new drugs, ranging from Fast track (1988), Accelerated approval (1992), Priority review (1992) to the most recent Breakthrough therapy (2012). This pipeline update, Cancer Drugs in the FDA Fast Lane, gives a thorough account on ... Read More

  • Mitochondrial Drugs in Oncology Drug Pipeline Update

    ... differences in mitochondrial functions between tumor and normal cells can be the key to design selective anti-cancer therapies. Compounds that directly affect mitochondrial functions are considered to present a promising alternative approach to eradicate chemotherapy-resistant ... Read More

  • EGFR1 Signaling Pathway in Oncology Drug Pipeline Update

    ... in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 379 drugs. Egfr1 Signaling Pathway In Oncology Drug Pipeline Update lists all ... Read More

  • IL-1 Signaling Pathway in Oncology Drug Pipeline Update 2015

    ... the MAPK signaling module and activate NFkB, they are synergistic and complement each other's activity. There are today 106 companies plus partners developing 103 IL-1 pathway targeting drugs in 407 developmental projects in cancer. In ... Read More

  • IL-3 Signaling Pathway in Oncology Drug Pipeline Update 2015

    ... drugs in 1156 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 126 drugs. Il-3 Signaling Pathway In Oncology ... Read More

  • IL-4 Signaling Pathway in Oncology Drug Pipeline Update 2015

    ... 937 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 100 drugs. Il-4 Signaling Pathway In Oncology Drug Pipeline ... Read More

  • IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2015

    ... 831 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 82 drugs. Il-5 Signaling Pathway In Oncology Drug Pipeline ... Read More

  • IL-6 Signaling Pathway in Oncology Drug Pipeline Update 2015

    ... drugs in 1553 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 194 drugs. Il-6 Signaling Pathway In Oncology ... Read More

  • IL-9 Signaling Pathway in Oncology Drug Pipeline Update 2015

    ... developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 33 drugs. Il-9 Signaling Pathway In Oncology Drug Pipeline Update ... Read More

  • Wnt Signaling Pathway in Oncology Drug Pipeline Update 2015

    ... are today 211 companies plus partners developing 222 Wnt pathway targeting drugs in 885 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last ... Read More

  • IL-2 Signaling Pathway in Oncology Drug Pipeline Update 2015

    ... drugs in 1560 developmental projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 179 drugs. Il-2 Signaling Pathway In Oncology ... Read More

  • CAR-T Therapies in Oncology Drug Pipeline Update 2015

    ... drug. In this regard, we have already witnessed the stellar results by Novartis and Penn University on CTL019 that left 92% of patients cancer-free in a leukemia study and performed well against lymphomas in clinical ... Read More

  • Bio-Europe 2014 Cancer Drug Pipeline Update 2015

    ... responsible for slightly more than 40% of the global oncology pipeline under active development. To reflect this importance, the analyst team at BioSeeker Group have identified 264 participating companies plus partners who are today actively ... Read More

1 2 3 4 5 6 7 9 Next >

Research Assistance

Join Alert Me Now!

Sign Up

Find out more on our blog

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook